NJ Justices OK Centralizing Abilify Side-Effect Suits

Law360 (May 10, 2018, 10:05 PM EDT) -- The New Jersey Supreme Court has agreed to give multicounty litigation designation to lawsuits against Bristol-Myers Squibb Co. and Otsuka America Pharmaceutical Inc. over certain side effects relating to the antipsychotic drug Abilify, according to a Wednesday notice to the bar.

The high court on Monday assigned the 42 cases pending in various Garden State counties to Atlantic County Superior Court Judge Nelson C. Johnson, after considering the parties' request to centralize the suit for management purposes and comments on the request, the notice said.

The suits allege that Abilify, which the U.S. Food and Drug Administration has approved to treat...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!